# Cholangitis

Acute cholangitis is biliary infection with potential for rapid sepsis and organ failure. Management hinges on immediate resuscitation and antibiotics, severity assessment, and timely biliary drainage when obstruction persists or disease is severe.

**Clinical question:** How should physicians recognize, stabilize, and obtain source control for suspected acute cholangitis?

Updated: 2026-08-21T00:36:48.322699+00:00

## What matters in practice
- Treat suspected acute cholangitis as a time-sensitive biliary sepsis syndrome: begin resuscitation and empiric antibiotics while arranging evaluation for obstruction and drainage. [9][20]
- Hypotension, multiorgan failure, or altered mental status identify a life-threatening presentation requiring urgent source-control planning. [9][20]
- Endoscopic biliary drainage is an effective initial intervention for severe cholangitis due to choledocholithiasis. [18]
- In PSC, cholangitis may occur without a major change from baseline liver biochemistries; prior ERCP and indwelling stents increase infectious risk. [12]

## Identify acute cholangitis as biliary infection with systemic risk

Do not require classic symptom complexes before initiating a sepsis-oriented evaluation.

Acute cholangitis is a life-threatening infection of the biliary tract. Clinical recognition should integrate jaundice, fever or chills, and right-upper-quadrant pain with laboratory evidence and imaging findings suggestive of biliary obstruction or infection. [20][24]

Charcot triad and Reynolds pentad are historically important but have limited diagnostic sensitivity; their absence should not defer treatment in a patient with suspected biliary sepsis. [20] Toxic or severe cholangitis is characterized by purulent biliary contents with sepsis, hypotension, multiorgan failure, or mental-status change. [9]
- Escalate immediately for hypotension, altered mental status, organ dysfunction, or other features of sepsis; these findings indicate a high-risk presentation in which delayed biliary decompression may be harmful. [9][20]
- In patients with PSC, evaluate compatible fever, rigors, abdominal pain, jaundice, or clinical deterioration even if liver tests are not substantially different from baseline. [12]

*Clinical findings that should change urgency in suspected cholangitis. [9][20][24]*

| Finding | Clinical implication |
| --- | --- |
| Jaundice, fever or chills, right-upper-quadrant pain with supportive laboratory and imaging findings | Supports acute cholangitis; begin sepsis-directed management while defining obstruction and drainage needs. [20][24] |
| Hypotension, multiorgan failure, altered mental status | Life-threatening or toxic cholangitis phenotype; urgent source-control planning is required. [9][20] |
| PSC with compatible infectious symptoms but little biochemical change | Do not exclude cholangitis on the basis of stable baseline liver tests alone. [12] |

## Stabilize and start empiric antimicrobial therapy before source control

Management should proceed in parallel rather than sequentially.

Early recognition, fluid resuscitation, broad-spectrum antibiotics, and biliary intervention have improved outcomes in acute cholangitis. [20] Obtain diagnostic studies and cultures when feasible without delaying antimicrobials or urgent drainage in unstable patients; the supplied sources do not provide a validated U.S. empiric regimen, dose, or treatment duration.

Antibiotic selection should therefore follow local biliary-infection pathways, prior culture data, recent antimicrobial exposure, health care exposure, renal function, allergy history, and the anticipated drainage procedure. This article does not specify drug doses because the supplied evidence does not support regimen-level recommendations.
- Resuscitate as for sepsis, with frequent reassessment of hemodynamics, mental status, oxygenation, urine output, and evolving organ dysfunction. [9][20]
- Obtain early gastroenterology/endoscopy and, when appropriate, interventional radiology or surgical consultation for anticipated biliary decompression. [18][20]
- Do not use improvement in laboratory values alone as a substitute for reassessment of ongoing obstruction or need for source control. This operational point is based on the central role of drainage in severe disease. [18][20]

*Parallel actions in suspected acute cholangitis. [9][18][20]*

| Priority | Action | Decision consequence |
| --- | --- | --- |
| Stabilization | Initiate sepsis-directed resuscitation and monitor for hypotension, organ failure, and altered mental status. [9][20] | Identifies patients requiring urgent escalation and source control. [9][20] |
| Infection treatment | Administer early empiric broad-spectrum antibiotics. [20] | Do not defer antimicrobial therapy while arranging definitive drainage. [20] |
| Source control | Assess for biliary obstruction and arrange biliary drainage, particularly in severe disease. [18][20] | Persistent obstruction or severe illness should lower the threshold for urgent intervention. [18][20] |

## Use biliary drainage to control obstruction-associated severe cholangitis

Drainage addresses the obstructed infected biliary system when medical therapy alone is insufficient.

For severe acute cholangitis caused by choledocholithiasis, endoscopic biliary drainage has been shown to be a safe and effective initial measure for control of the acute episode. [18] ERCP-based therapy is therefore central when endoscopic access is feasible and prompt decompression is needed.

Stone-directed definitive management may follow stabilization. In a reported management approach for gallstone cholangitis, ERCP with endoscopic sphincterotomy was followed by interval laparoscopic cholecystectomy. [17] The supplied sources do not establish a universal timing target for ERCP, specify a preferred endoscopic technique for every obstruction, or support recommendations on post-drainage antibiotic duration.
- Prioritize urgent drainage in severe disease, especially with sepsis physiology or organ dysfunction. [9][18][20]
- Use multidisciplinary planning when ERCP is unavailable, unsuccessful, or anatomically impractical; the supplied sources do not provide comparative evidence to rank alternative drainage methods.
- After biliary instrumentation, monitor for recurrent infection and procedure-related complications; in PSC, risk is particularly relevant when stents remain in place. [12]

*Drainage-related decisions supported by the available evidence. [12][17][18]*

| Scenario | Management implication |
| --- | --- |
| Severe cholangitis from choledocholithiasis | Endoscopic biliary drainage is an effective initial control strategy. [18] |
| Gallstone cholangitis after endoscopic treatment | ERCP with sphincterotomy followed by interval laparoscopic cholecystectomy has been reported as a management approach. [17] |
| PSC after ERCP or with an indwelling stent | Maintain a high index of suspicion for cholangitis; prior instrumentation and retained stents are associated with higher bacterobilia and infection risk. [12] |

## Recognize cholangitis in primary sclerosing cholangitis

PSC changes the interpretation of laboratory tests and procedural risk.

Cholangitis is a common complication of PSC. Infection may be segmental and can occur without a significant change in baseline liver biochemistry, so clinical assessment and evaluation for a relevant stricture or other biliary complication are important. [12]

Previous ERCP, therapeutic intervention, and especially retained biliary stents are risk factors for bacterobilia and cholangitis in PSC. [12] A patient with PSC and suspected cholangitis should be managed with early specialist involvement because the differential includes clinically significant stricture and cholangiocarcinoma.
- Refer clinically suspected cholangiocarcinoma in PSC for specialist multidisciplinary review. [12]
- For adult PSC, AGA expert review advises considering surveillance for cholangiocarcinoma and gallbladder cancer using ultrasound, CT, or MRI, with or without CA 19-9, every 6 to 12 months. [23]
- Gallbladder polyps larger than 8 mm in PSC carry increased gallbladder-cancer risk in the AGA review; operative decisions should also consider growth and clinical status. [23]

## Reassess response and address the cause of obstruction

Disposition depends on physiologic trajectory and adequacy of source control.

Continue close reassessment after antibiotics and drainage for hemodynamic improvement, resolution of organ dysfunction, and evidence that biliary source control is adequate. Severe cholangitis requires a level of monitoring capable of managing sepsis and rapidly escalating organ support. [9][20]

For gallstone-associated disease, transition from acute decompression to a definitive plan for stone disease and cholecystectomy when clinically appropriate. [17] In PSC or when a malignancy-associated obstruction is suspected, coordinate follow-up with hepatology, therapeutic endoscopy, surgery, oncology, and multidisciplinary review as indicated. [12][23]
- Re-evaluate recurrent fever, sepsis, or failure to improve for unresolved obstruction, inadequate drainage, a stent-related complication, or an alternative diagnosis. This is consistent with the need for source control in severe disease and the instrumentation-associated risk observed in PSC. [12][18][20]
- Do not infer a specific antibiotic stop date from this review; duration after successful drainage is not provided in the supplied sources.

## Common questions

### Does absence of Charcot triad exclude acute cholangitis?

No. Classic symptom complexes have poor sensitivity. Diagnose using the overall clinical syndrome, laboratory findings, and imaging evidence of biliary disease, and do not delay treatment in a patient with suspected biliary sepsis. [20][24]

### When is biliary drainage most urgent?

Urgency is highest with severe disease, particularly hypotension, altered mental status, multiorgan failure, or other sepsis physiology. Endoscopic biliary drainage is an effective initial intervention for severe cholangitis due to choledocholithiasis. [9][18][20]

### Can PSC-associated cholangitis occur with stable liver tests?

Yes. PSC-related infection may be limited to small hepatic segments and may not produce a significant change in baseline liver biochemistry. Prior ERCP and retained stents further increase infectious risk. [12]

### What surveillance is considered for hepatobiliary cancer in PSC?

AGA expert review advises considering ultrasound, CT, or MRI, with or without CA 19-9, every 6 to 12 months for cholangiocarcinoma and gallbladder-cancer surveillance in adult PSC. [23]

## References
1. CENTER FOR DRUG EVALUATION AND RESEARCH — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203214Orig1s018.pdf
2. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211810s007lbl.pdf
3. 207999Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207999Orig1s000CrossR.pdf
4. 1f9cc1ab-687d-eb66-9b7f-867cca0600fb.xml — www.accessdata.fda.gov — https://www.accessdata.fda.gov/spl/data/1f9cc1ab-687d-eb66-9b7f-867cca0600fb/1f9cc1ab-687d-eb66-9b7f-867cca0600fb.xml
5. https://nctr-crs.fda.gov/fdalabel/services/spl/ ... — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/08cf2861-2483-405d-a872-a88a5c235f9a/spl-doc
6. highlights of prescribing information — www.fda.gov — https://www.fda.gov/media/180873/download
7. Pharmacokinetics in Patients with Impaired Hepatic Function — www.fda.gov — https://www.fda.gov/media/71311/download
8. Guideline Update: Primary Sclerosing Cholangitis | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/guideline-update-primary-sclerosing-cholangitis-JG201003260000002
9. Acute cholangitis - Symptoms, diagnosis and treatment — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/345
10. Primary sclerosing cholangitis - Symptoms, diagnosis and ... — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/847
11. Primary biliary cholangitis - Symptoms, diagnosis and ... — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/344
12. British Society of Gastroenterology and UK-PSC guidelines ... — gut.bmj.com — https://gut.bmj.com/content/68/8/1356
13. Prognostic factors for transplant-free survival in patients ... — bmjopengastro.bmj.com — https://bmjopengastro.bmj.com/content/12/1/e001571
14. The British Society of Gastroenterology/UK-PBC primary ... — gut.bmj.com — https://gut.bmj.com/content/67/9/1568
15. Treatment of cholangiocarcinoma in patients with primary ... — egastroenterology.bmj.com — https://egastroenterology.bmj.com/content/2/1/e100045
16. Acute cholecystitis - Symptoms, diagnosis and treatment — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/78
17. Management of Gallstone Cholangitis in the Era ... — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/390880
18. Endoscopic Biliary Drainage for Severe Acute Cholangitis — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199206113262401
19. ACG Clinical Guideline: Primary Sclerosing Cholangitis — www.nature.com — https://www.nature.com/articles/ajg2015112.pdf?origin=ppub
20. The Emergency Medicine−Focused Review of Cholangitis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0736467917306157
21. Official journal of the American College of Gastroenterology | ACG — journals.lww.com — https://journals.lww.com/ajg/fulltext/2017/09000/strategies_to_combat_physician_burnout_in.2.aspx
22. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states community - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0016508503013568
23. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S154235651930744X
24. Diagnostic Imaging of Suspected Acute Cholecystitis and ... — academic.oup.com — https://academic.oup.com/cid/article/79/Supplement_3/S104/7706134

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.